Curanex Pharmaceuticals Inc Common Stock Cash Flow Conversion Efficiency
Curanex Pharmaceuticals Inc Common Stock cash flow conversion efficiency. Based on the latest financial reports, Curanex Pharmaceuticals Inc Common Stock (CURX) has a cash flow conversion efficiency ratio of -0.643x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.19 Million) by net assets ($14.29 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Curanex Pharmaceuticals Inc Common Stock (2022–2024)
Cash flow conversion efficiency of Curanex Pharmaceuticals Inc Common Stock from 2022 to 2024. This chart illustrates how Curanex Pharmaceuticals Inc Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View CURX stock price and chart for real-time trading data and today's change.
Curanex Pharmaceuticals Inc Common Stock Cash Flow Conversion Ratio Explained
Curanex Pharmaceuticals Inc Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Curanex Pharmaceuticals Inc Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Curanex Pharmaceuticals Inc Common Stock ranked by their cash flow conversion efficiency. Also see market value of Curanex Pharmaceuticals Inc Common Stock for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
A.G.Barr PLC
LSE:BAG
|
0.103x |
|
Green Technology Metals Ltd
AU:GT1
|
-0.017x |
|
Focus Dynamics Group Bhd
KLSE:0116
|
0.047x |
|
Nimy Resources Ltd
AU:NIM
|
-0.130x |
|
Mandrake Resources Ltd
AU:MAN
|
-0.002x |
|
Corus Entertainment Inc
TO:CJR-B
|
0.077x |
|
Natural Health Trends Corp
F:NAH
|
-0.048x |
|
Quhuo Limited American Depository Shares
NASDAQ:QH
|
0.005x |
Annual Cash Flow Conversion Efficiency for Curanex Pharmaceuticals Inc Common Stock (2022–2024)
The table below shows the annual cash flow conversion efficiency of Curanex Pharmaceuticals Inc Common Stock from 2022 to 2024. Review CURX free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $503.36K | $-555.58K | -1.104x | -55169.43% |
| 2023-12-31 | $60.09K | $-120.00 | -0.002x | -100.61% |
| 2022-12-31 | $10.23K | $3.34K | 0.326x | -- |
About Curanex Pharmaceuticals Inc Common Stock
Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients suffering from inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The company was formerly known as Fordman Pharma… Read more